Search - tctmd.com

Displaying 81 - 100 of 929

Sort: Relevancy | Date

News Industry News

Essentials of Clinical Trial Design: Statistics 101 for the Budding Interventionalist

May 13, 2021

News Daily News

Add-on CMS Payment Sweetens Shockwave Choice, but Cost Still Rankles

Michael O'Riordan

May 12, 2021

News Conference News ACC 2021

Even With Stent Cards, Patients Often Hazy on PCI Details Years Later

Michael O'Riordan

May 11, 2021

News Daily News CRT 2021

COMPARE-ABSORB: 3-Year Results Hint at Stabilization With Bioresorbable Scaffold

Michael O'Riordan

March 17, 2021

News Daily News

Invasive Approach Best for Cocaine-Linked NSTEMI, but DAPT Is Key

Michael O'Riordan

March 16, 2021

News Conference News CRT 2021

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

Caitlin E. Cox

March 16, 2021

News Daily News

No Harm, No Help With Bioabsorbable-Polymer Stents: Registry

Michael O'Riordan

March 01, 2021

News Daily News

Site Investigators Missed Clinical Events in GLOBAL LEADERS

Michael O'Riordan

February 12, 2021

News Conference News

‘Healing’ Stent Noninferior to Permanent-Polymer Device: PIONEER III

Shelley Wood

November 19, 2020

News Conference News AHA 2020

Latest Post-DES Drug Trial Tests Aspirin Monotherapy After 1 Month of DAPT

Shelley Wood

November 15, 2020

News Conference News TCT 2020

EXAMINATION Surprise: Few Late Event Gaps Between DES and BMS in STEMI

L.A. McKeown

October 22, 2020

Direct Temsirolimus Delivery Shows Promise in BTK: Phase II Study

News Conference News TCT 2020

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

Caitlin E. Cox

October 18, 2020

News Industry News

CeloNova Announces Late-Breaking Evidence from First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT in Complex Patients at High Bleeding Risk Following PCI

October 17, 2020

News Conference News TCT 2020

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

Shelley Wood

October 17, 2020

In-Stent Restenosis Accounts for 10% of All PCIs, Contemporary National Analysis Shows

News Daily News

In-Stent Restenosis Accounts for 10% of All PCIs, National Analysis Shows

L.A. McKeown

September 24, 2020

News Conference News ESC 2020

In Long-term, Real-world Data, CABG Bests PCI for Diabetic Patients With MVD

Yael L. Maxwell

September 01, 2020

News Daily News

Analysis Supports Short DAPT Followed by P2Y12 Inhibitor Monotherapy After DES PCI

L.A. McKeown

August 10, 2020

News Daily News

Polymer-Free DES Hold No Long-term Advantage: ISAR-TEST-5

Michael O'Riordan

July 07, 2020

News Industry News

CeloNova Announces Enrollment Completion of World’s First Randomized Control, 14-Day DAPT Trial

June 01, 2020

News Daily News

Clopidogrel Holds Advantage in Older NTSE ACS Patients: POPular AGE Published

Michael O'Riordan

April 27, 2020

Advertisement

Essentials of Clinical Trial Design: Statistics 101 for the Budding Interventionalist

Add-on CMS Payment Sweetens Shockwave Choice, but Cost Still Rankles

Even With Stent Cards, Patients Often Hazy on PCI Details Years Later

COMPARE-ABSORB: 3-Year Results Hint at Stabilization With Bioresorbable Scaffold

Invasive Approach Best for Cocaine-Linked NSTEMI, but DAPT Is Key

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

No Harm, No Help With Bioabsorbable-Polymer Stents: Registry

Site Investigators Missed Clinical Events in GLOBAL LEADERS

‘Healing’ Stent Noninferior to Permanent-Polymer Device: PIONEER III

Latest Post-DES Drug Trial Tests Aspirin Monotherapy After 1 Month of DAPT

EXAMINATION Surprise: Few Late Event Gaps Between DES and BMS in STEMI

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

CeloNova Announces Late-Breaking Evidence from First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT in Complex Patients at High Bleeding Risk Following PCI

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

In-Stent Restenosis Accounts for 10% of All PCIs, National Analysis Shows

In Long-term, Real-world Data, CABG Bests PCI for Diabetic Patients With MVD

Analysis Supports Short DAPT Followed by P2Y12 Inhibitor Monotherapy After DES PCI

Polymer-Free DES Hold No Long-term Advantage: ISAR-TEST-5

CeloNova Announces Enrollment Completion of World’s First Randomized Control, 14-Day DAPT Trial

Clopidogrel Holds Advantage in Older NTSE ACS Patients: POPular AGE Published

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content